JP5573679B2 - マラリアワクチン組成物および細胞媒介免疫性を惹起する成分 - Google Patents
マラリアワクチン組成物および細胞媒介免疫性を惹起する成分 Download PDFInfo
- Publication number
- JP5573679B2 JP5573679B2 JP2010543174A JP2010543174A JP5573679B2 JP 5573679 B2 JP5573679 B2 JP 5573679B2 JP 2010543174 A JP2010543174 A JP 2010543174A JP 2010543174 A JP2010543174 A JP 2010543174A JP 5573679 B2 JP5573679 B2 JP 5573679B2
- Authority
- JP
- Japan
- Prior art keywords
- epitopes
- csp
- polyepitope
- sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
上述の非限定的実施例は、本発明をさらに説明するために役立つ。
Claims (4)
- アミノ酸配列MMRKLAILSVSSFLFVEALFQEYQCYGSSKMEKCSSVFNVVNSSIGLIMVLSFLFLN(配列番号38)の1個以上のコピーを含む組換え抗原性ポリペプチド。
- 前記アミノ酸配列の多コピーが存在するとともに、i)互いに直接隣接して配置されているかまたはii)前記組換え抗原性ポリペプチド内部において正統的カルボキシ末端タンパク質分解切断を可能とするスペーサーペプチドによって互いに分離されていることを特徴とする請求項1記載の組換え抗原性ポリペプチド。
- 請求項1記載の抗原性ポリペプチドをコードする核酸。
- 前記アミノ酸配列の多コピーが存在するとともに、i)互いに直接隣接して配置されているかまたはii)前記組換え抗原性ポリペプチド内部において正統的カルボキシ末端タンパク質分解切断を可能とするスペーサーペプチドによって互いに分離されていることを特徴とする請求項3記載の核酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2199608P | 2008-01-18 | 2008-01-18 | |
US61/021,996 | 2008-01-18 | ||
PCT/US2009/030734 WO2009091692A2 (en) | 2008-01-18 | 2009-01-12 | Malaria vaccine compositions and constituents which elicit cell mediated immunity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011509672A JP2011509672A (ja) | 2011-03-31 |
JP5573679B2 true JP5573679B2 (ja) | 2014-08-20 |
Family
ID=40885869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010543174A Active JP5573679B2 (ja) | 2008-01-18 | 2009-01-12 | マラリアワクチン組成物および細胞媒介免疫性を惹起する成分 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8728492B2 (ja) |
EP (1) | EP2249857A4 (ja) |
JP (1) | JP5573679B2 (ja) |
CN (1) | CN101969991A (ja) |
BR (1) | BRPI0905729A2 (ja) |
WO (1) | WO2009091692A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9115205B2 (en) | 2010-10-18 | 2015-08-25 | The United States Of America, As Represented By The Secretary Of The Army | Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression |
US9645147B2 (en) * | 2012-11-09 | 2017-05-09 | The United States Of America As Represented By The Secretary Of The Navy | Recombinant polypeptide construct comprising Plasmodium falciparum circumsporozoite protein HLA class I restricted T-cell epitopes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3686178T2 (de) * | 1985-02-07 | 1993-03-11 | Smithkline Beckman Corp | Malaria-impfstoff. |
BR8707471A (pt) * | 1986-09-22 | 1988-09-13 | Univ Emory | Vacina e processo de preparacao |
EP1064022A4 (en) * | 1998-03-13 | 2004-09-29 | Epimmune Inc | HLA BINDING PEPTIDES AND THEIR APPLICATIONS |
WO2004002415A2 (en) * | 2002-06-27 | 2004-01-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
CN101077416A (zh) * | 2002-10-23 | 2007-11-28 | 葛兰素史密丝克莱恩生物有限公司 | 抗疟疾的疫苗接种方法 |
US8232255B2 (en) * | 2002-10-23 | 2012-07-31 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
US8017745B2 (en) * | 2002-12-06 | 2011-09-13 | Epimmune Inc. | Plasmodium falciparum antigens and methods of use |
WO2006019427A2 (en) | 2004-04-14 | 2006-02-23 | The Governement Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Compositions and methods for prophylaxis, treatment and detection of malarial infections |
CN101595127B (zh) | 2006-12-21 | 2013-11-06 | 大主教研究中心生物医学基金会 | 用于诱导脊椎动物发生免疫应答的、包含有涵盖了单种抗原ama1的异质性的大量蛋白质变体的蛋白质组合物 |
-
2009
- 2009-01-12 BR BRPI0905729-3A patent/BRPI0905729A2/pt not_active IP Right Cessation
- 2009-01-12 JP JP2010543174A patent/JP5573679B2/ja active Active
- 2009-01-12 CN CN200980107256XA patent/CN101969991A/zh active Pending
- 2009-01-12 EP EP09701498A patent/EP2249857A4/en not_active Withdrawn
- 2009-01-12 US US12/863,040 patent/US8728492B2/en active Active
- 2009-01-12 WO PCT/US2009/030734 patent/WO2009091692A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2009091692A2 (en) | 2009-07-23 |
EP2249857A4 (en) | 2012-02-29 |
US8728492B2 (en) | 2014-05-20 |
WO2009091692A3 (en) | 2009-10-08 |
EP2249857A2 (en) | 2010-11-17 |
CN101969991A (zh) | 2011-02-09 |
JP2011509672A (ja) | 2011-03-31 |
BRPI0905729A2 (pt) | 2015-07-14 |
US20110206714A1 (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Starnbach et al. | An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response | |
US11135277B2 (en) | Antigen specific multi epitope-based anti-infective vaccines | |
KR20010072112A (ko) | 암 억제 유전자 더블유티1의 생산물에 기초한 암항원 | |
JP7035063B2 (ja) | phoP-phoRを過剰発現する組換えBCG | |
US9499809B2 (en) | CyaA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses | |
Jensen et al. | Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani | |
Caro-Aguilar et al. | Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria | |
JPH11506320A (ja) | 豊富な細胞外産物、ならびにそれらを産生および使用するための方法 | |
US10213501B2 (en) | Three-component-multistage malaria vaccine | |
CA2783107C (en) | Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins | |
US9314517B2 (en) | Parasite vaccine | |
CN107551264B (zh) | L3和/或l5源作为寄生虫病疫苗或诊断的用途 | |
JP5573679B2 (ja) | マラリアワクチン組成物および細胞媒介免疫性を惹起する成分 | |
JP5055522B2 (ja) | 多包条虫由来の新規蛋白質 | |
CN105367662B (zh) | 一种hbv相关的融合蛋白、其制备方法及其应用 | |
US20150203547A1 (en) | Use of p47 from plasmodium falciparum (pfs47) or plasmodium vivax (pvs47) as a vaccine or drug screening targets for the inhibition of human malaria transmission | |
KR20110060865A (ko) | 리슈마니아증 및 결핵에 대한 백신 개발을 위한 dna 키메라의 작제 | |
EP3722307A1 (en) | Tick vaccine for companion animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130625 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130918 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140519 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140616 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5573679 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |